Cover Image
市場調查報告書

PharmaPoint:B型肝炎病毒(HBV)預防疫苗 - 全球醫藥品的預測與市場分析

PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Global Drug Forecast and Market Analysis to 2022

出版商 GlobalData 商品編碼 298048
出版日期 內容資訊 英文 303 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:B型肝炎病毒(HBV)預防疫苗 - 全球醫藥品的預測與市場分析 PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Global Drug Forecast and Market Analysis to 2022
出版日期: 2014年01月31日 內容資訊: 英文 303 Pages
簡介

B型肝炎是由B型肝炎病毒(HBV)所引起的急性或慢性肝炎。全球HBV的感染者數約20億人,HBV相關的肝疾病每年約造成60萬人死亡。 雖然由於基因重組HBV表面抗原(HBsAg)疫苗在過去二十年大大減輕了疾病的負擔,但仍留有成人疫苗攝取及有效性的疑問。

本報告提供全球B型肝炎病毒(HBV)預防疫苗市場相關調查分析,提供疾病的概要與指南,競爭情形,主要藥物的詳細資訊(產品說明,安全性,有效性),彙整SWOT分析,銷售額預測,影響分析(趨勢,推動因素·阻礙因素)等,為您概述為以下內容。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 概要
  • 病因·病理生理學
  • 症狀
  • 預測

第4章 疫苗接種建議與接種率

  • 概要
  • 美國
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 日本
  • 加拿大

第5章 競爭評估

  • 概要
  • 策略性競爭企業的評估
  • 產品簡介 - 單價疫苗
  • 產品簡介 - 混合疫苗

第6章 機會及未滿足需求

  • 概要
  • 疫苗免疫抗原性的增加
  • 疫苗接種率的增加
  • 患者意識的提升
  • 醫生教育的提升
  • 高成本效益的疫苗

第7章 開發平台評估

  • 概要
  • 臨床實驗設計
  • 後期階段臨床開發的有潛力疫苗
  • 初期階段臨床開發的有潛力疫苗

第8章 現在/未來的主要企業

  • 概要
  • 企業策略趨勢
  • 企業簡介
    • GSK
    • Merck
    • Sanofi
    • Kaketsuken
    • Dynavax Technologies

第9章 市場預測

  • 全球市場
  • 美國
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 日本
  • 加拿大

第10章 附錄

圖表

目錄
Product Code: GDHC68PIDR

Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year from HBV-related liver diseases. While the arrival of recombinant HBsAg vaccines has greatly reduced disease burden over the past two decades, questions surrounding vaccine uptake and effectiveness in adults, particularly in niche patient populations, still remain. GlobalData expects that the growing popularity of pediatric combination vaccines, along with the arrival of vaccines that achieve higher seroconversion rates in high-risk adults, will serve to stimulate growth in the marketplace over the forecast period. Country-specific immunization recommendations and policy implementation will be an essential metric for determining future vaccine uptake in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan) and Canada.

Highlights

Key Questions Answered

  • How large an impact will Hexyon and Heplisav have on the HBV vaccine market? What do key opinion leaders think of these vaccines?
  • What are the key HBV vaccines for each age segment and country?
  • Which HBV vaccines will face adoption challenges in the market? What is the projected uptake of new vaccines, such as Dynavax's Heplisav, over the forecast period?
  • The developmental pipeline consists of vaccines that address immunogenicity and coverage rate concerns. Which of these vaccines will attain high sales revenues during 2012-2022 and in which markets?
  • What governmental and industry developments are likely to affect the vaccination rates in the markets researched? Which is the largest growth market globally?

Key Findings

  • Country-specific immunization recommendations heavily influence HBV vaccine uptake in the pediatric and adult segments of the marketplace.
  • The potential impact of Dynavax Technologies' Heplisav on the marketplace will be determined by its level of uptake in at-risk adults targeted for vaccination.
  • Major players will leverage their R&D, manufacturing, and distribution networks to maintain their stakes in the market.
  • Government endorsements of new and existing vaccines, in particular pediatric combination vaccines and novel adult vaccines, are anticipated to dramatically influence market growth.

Scope

  • Overview of hepatitis B virus (HBV), including etiology, general symptoms from infection, and country-specific immunization recommendations and vaccination coverage data.
  • Annualized HBV vaccine market revenue, annual cost of vaccination and treatment usage pattern data from 2012 and forecast for ten years to 2022.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the HBV vaccine market.
  • Pipeline analysis: comprehensive data split across different phases and emerging trends, specifically Dynavax Technologies' Heplisav and Sanofi Pasteur MSD's Hexyon.
  • Analysis of the current and future market competition in the global HBV vaccine market. Insightful review of the key industry and governmental drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the HBV vaccine market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global HBV vaccine market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global HBV vaccine market from 2012-2022.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Overview
  • 3.2. Etiology and Pathophysiology
    • 3.2.1. Etiology
    • 3.2.2. Pathophysiology
  • 3.3. Symptoms
  • 3.4. Prognosis

4. Vaccination Recommendations and Coverage Rates

  • 4.1. Overview
  • 4.2. US
    • 4.2.1. Immunization Recommendations and Policies
    • 4.2.2. Vaccination Coverage
    • 4.2.3. Clinical Practice
  • 4.3. France
    • 4.3.1. Immunization Recommendations and Policies
    • 4.3.2. Vaccination Coverage
    • 4.3.3. Clinical Practice
  • 4.4. Germany
    • 4.4.1. Immunization Recommendations and Policies
    • 4.4.2. Vaccination Coverage
    • 4.4.3. Clinical Practice
  • 4.5. Italy
    • 4.5.1. Immunization Recommendations and Policies
    • 4.5.2. Vaccination Coverage
    • 4.5.3. Clinical Practice
  • 4.6. Spain
    • 4.6.1. Immunization Recommendations and Policies
    • 4.6.2. Vaccination Coverage
    • 4.6.3. Clinical Practice
  • 4.7. UK
    • 4.7.1. Immunization Recommendations and Policies
    • 4.7.2. Vaccination Coverage
    • 4.7.3. Clinical Practice
  • 4.8. Japan
    • 4.8.1. Immunization Recommendations and Policies
    • 4.8.2. Vaccination Coverage
    • 4.8.3. Clinical Practice
  • 4.9. Canada
    • 4.9.1. Immunization Recommendations and Policies
    • 4.9.2. Vaccination Coverage
    • 4.9.3. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment
  • 5.3. Product Profiles - Monovalent Vaccines
    • 5.3.1. Engerix-B
    • 5.3.2. Recombivax HB
    • 5.3.3. Fendrix
    • 5.3.4. Bimmugen
  • 5.4. Product Profiles - Combination Vaccines
    • 5.4.1. Infanrix Hexa
    • 5.4.2. Pediarix
    • 5.4.3. Hexyon
    • 5.4.4. Comvax
    • 5.4.5. Twinrix
    • 5.4.6. Ambirix

6. Opportunity and Unmet Need

  • 6.1. Overview
  • 6.2. Increased Vaccine Immunogenicity
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Increased Vaccination Coverage Rates
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Increased Patient Awareness
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Improved Physician Education
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity
  • 6.6. More Cost-Effective Vaccines
    • 6.6.1. Unmet Need
    • 6.6.2. Gap Analysis
    • 6.6.3. Opportunity

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Clinical Trial Mapping
    • 7.2.1. Clinical Trials by Country
    • 7.2.2. Clinical Trials by Phase and Trial Status
  • 7.3. Promising Vaccines in Late-Stage Clinical Development
    • 7.3.1. Heplisav
  • 7.4. Promising Vaccines in Early-Stage Clinical Development

8. Current and Future Players

  • 8.1. Overview
  • 8.2. Trends in Corporate Strategy
  • 8.3. Company Profiles
    • 8.3.1. GSK
    • 8.3.2. Merck
    • 8.3.3. Sanofi
    • 8.3.4. Kaketsuken
    • 8.3.5. Dynavax Technologies

9. Market Outlook

  • 9.1. Global Markets
    • 9.1.1. Forecast
    • 9.1.2. Drivers and Barriers - Global Issues
  • 9.2. US
    • 9.2.1. Forecast
    • 9.2.2. Key Events
    • 9.2.3. Drivers and Barriers
  • 9.3. France
    • 9.3.1. Forecast
    • 9.3.2. Key Events
    • 9.3.3. Drivers and Barriers
  • 9.4. Germany
    • 9.4.1. Forecast
    • 9.4.2. Key Events
    • 9.4.3. Drivers and Barriers
  • 9.5. Italy
    • 9.5.1. Forecast
    • 9.5.2. Key Events
    • 9.5.3. Drivers and Barriers
  • 9.6. Spain
    • 9.6.1. Forecast
    • 9.6.2. Key Events
    • 9.6.3. Drivers and Barriers
  • 9.7. UK
    • 9.7.1. Forecast
    • 9.7.2. Key Events
    • 9.7.3. Drivers and Barriers
    • 9.7.4. Alternative Market Scenario
  • 9.8. Japan
    • 9.8.1. Forecast
    • 9.8.2. Drivers and Barriers
  • 9.9. Canada
    • 9.9.1. Forecast
    • 9.9.2. Key Events
    • 9.9.3. Drivers and Barriers

10. Appendix

  • 10.1. Bibliography
  • 10.2. Abbreviations
  • 10.3. Methodology
  • 10.4. Forecasting Methodology
    • 10.4.1. Patient Populations Targeted for Vaccination
    • 10.4.2. Vaccination Coverage Rates
    • 10.4.3. Vaccinated Patients
    • 10.4.4. Regulatory Approval vs. Advisory Committee Recommendation
    • 10.4.5. Vaccines Included
    • 10.4.6. Key Launch Dates
    • 10.4.7. General Pricing Assumptions
    • 10.4.8. Individual Vaccine Assumptions
    • 10.4.9. Pricing of Pipeline Vaccines
  • 10.5. Physicians and Specialists Included in this Study
    • 10.5.1. Interviews of Key Opinion Leaders (KOLs)
    • 10.5.2. Online Survey of High-Prescribing Physicians (non-KOLs)
  • 10.6. About the Authors
    • 10.6.1. Analyst
    • 10.6.2. Therapy Area Director
    • 10.6.3. Global Head of Healthcare
  • 10.7. About GlobalData
  • 10.8. Disclaimer

List of Tables

  • Table 1: Modes of HBV Transmission
  • Table 2: HBV Serological Markers and Test Interpretations
  • Table 3: Symptoms of HBV Infection
  • Table 4: HBV Vaccination Advisory Committees by Country
  • Table 5: HBV Immunization Recommendations by Country
  • Table 6: Targeted Age Group(s) for Routine Immunization and Most Administered HBV Vaccines by Country in the Global Markets, 2014
  • Table 7: Targeted Age Group(s) for Routine HBV Immunization in Canada, by Province or Territory, 2014
  • Table 8: Leading Vaccines for HBV, 2014
  • Table 9: Product Profile - Engerix-B
  • Table 10: Immunogenicity Profile - Engerix-B
  • Table 11: Safety Profile - Engerix-B
  • Table 12: Engerix-B SWOT Analysis, 2014
  • Table 13: Global Sales Forecasts ($m) for Engerix-B, 2012-2022
  • Table 14: Product Profile - Recombivax HB
  • Table 15: Immunogenicity Profile - Recombivax HB
  • Table 16: Safety Profile - Recombivax HB
  • Table 17: Recombivax HB SWOT Analysis, 2014
  • Table 18: Global Sales Forecasts ($m) for Recombivax HB, 2012-2022
  • Table 19: Product Profile - Fendrix
  • Table 20: Immunogenicity Profile - Fendrix
  • Table 21: Safety Profile - Fendrix
  • Table 22: Fendrix SWOT Analysis, 2014
  • Table 23: Global Sales Forecasts ($m) for Fendrix, 2012-2022
  • Table 24: Product Profile - Bimmugen
  • Table 25: Bimmugen SWOT Analysis, 2014
  • Table 26: Global Sales Forecasts ($m) for Bimmugen, 2012-2022
  • Table 27: Product Profile - Infanrix Hexa
  • Table 28: Immunogenicity Profile - Infanrix Hexa
  • Table 29: Safety Profile - Infanrix Hexa
  • Table 30: Infanrix Hexa SWOT Analysis, 2014
  • Table 31: Global Sales Forecasts ($m) for Infanrix Hexa, 2012-2022
  • Table 32: Product Profile - Pediarix
  • Table 33: Immunogenicity Profile - Pediarix
  • Table 34: Safety Profile - Pediarix
  • Table 35: Pediarix SWOT Analysis, 2014
  • Table 36: Global Sales Forecasts ($m) for Pediarix, 2012-2022
  • Table 37: Product Profile - Hexyon
  • Table 38: Immunogenicity Profile - Hexyon
  • Table 39: Safety Profile - Hexyon
  • Table 40: Hexyon SWOT Analysis, 2014
  • Table 41: Global Sales Forecasts ($m) for Hexyon, 2012-2022
  • Table 42: Product Profile - Comvax
  • Table 43: Immunogenicity Profile - Comvax
  • Table 44: Safety Profile - Comvax
  • Table 45: Comvax SWOT Analysis, 2014
  • Table 46: Global Sales Forecasts ($m) for Comvax, 2012-2022
  • Table 47: Product Profile - Twinrix
  • Table 48: Immunogenicity Profile - Twinrix
  • Table 49: Safety Profile - Twinrix
  • Table 50: Twinrix SWOT Analysis, 2014
  • Table 51: Global Sales Forecasts ($m) for Twinrix, 2012-2022
  • Table 52: Product Profile - Ambirix
  • Table 53: Immunogenicity Profile - Ambirix
  • Table 54: Safety Profile - Ambirix
  • Table 55: Ambirix SWOT Analysis, 2014
  • Table 56: Global Sales Forecasts ($m) for Ambirix, 2012-2022
  • Table 57: Unmet Need and Opportunity in Prophylactic HBV Vaccines
  • Table 58: HBV Vaccines - Clinical Trials by Phase and Status, 2014
  • Table 59: HBV Vaccines - Phase Pipeline, 2014
  • Table 60: Comparison of Vaccines in Development for HBV, 2014
  • Table 61: Product Profile - Heplisav
  • Table 62: Immunogenicity Profile - Heplisav
  • Table 63: Safety Profile - Heplisav
  • Table 64: Heplisav SWOT Analysis, 2014
  • Table 65: Global Sales Forecasts ($m) for Heplisav, 2012-2022
  • Table 66: Key Companies in the HBV Vaccine Market, 2014
  • Table 67: GSK's HBV Vaccine Portfolio Assessment, 2014
  • Table 68: GSK SWOT Analysis, 2014
  • Table 69: Merck's HBV Vaccine Portfolio Assessment, 2014
  • Table 70: Merck SWOT Analysis, 2014
  • Table 71: Sanofi's HBV Vaccine Portfolio Assessment, 2014
  • Table 72: Sanofi SWOT Analysis, 2014
  • Table 73: Kaketsuken's HBV Vaccine Portfolio Assessment, 2014
  • Table 74: Kaketsuken SWOT Analysis, 2014
  • Table 75: Dynavax Technologies' HBV Vaccine Portfolio Assessment, 2014
  • Table 76: Dynavax Technologies SWOT Analysis, 2014
  • Table 77: Global Sales Forecasts ($m) for HBV Vaccines, 2012-2022
  • Table 78: Global HBV Vaccine Market - Drivers and Barriers, 2014
  • Table 79: Sales Forecasts ($m) for HBV Vaccines in the United States, 2012-2022
  • Table 80: Key Events Impacting Sales for HBV Vaccines in the United States, 2014
  • Table 81: United States HBV Vaccine Market - Drivers and Barriers, 2014
  • Table 82: Sales Forecasts ($m) for HBV Vaccines in France, 2012-2022
  • Table 83: Key Events Impacting Sales for HBV Vaccines in France, 2014
  • Table 84: France HBV Vaccine Market - Drivers and Barriers, 2014
  • Table 85: Sales Forecasts ($m) for HBV Vaccines in Germany, 2012-2022
  • Table 86: Key Events Impacting Sales for HBV Vaccines in Germany, 2014
  • Table 87: Germany HBV Vaccine Market - Drivers and Barriers, 2014
  • Table 88: Sales Forecasts ($m) for HBV Vaccines in Italy, 2012-2022
  • Table 89: Key Events Impacting Sales for HBV Vaccines in Italy, 2014
  • Table 90: Italy HBV Vaccine Market - Drivers and Barriers, 2014
  • Table 91: Sales Forecasts ($m) for HBV Vaccines in Spain, 2012-2022
  • Table 92: Key Events Impacting Sales for HBV Vaccines in Spain, 2014
  • Table 93: Spain HBV Vaccine Market - Drivers and Barriers, 2014
  • Table 94: Sales Forecasts ($) for HBV Vaccines in the United Kingdom, 2012-2022
  • Table 95: Key Events Impacting Sales for HBV Vaccines in the United Kingdom, 2014
  • Table 96: United Kingdom HBV Vaccine Market - Drivers and Barriers, 2014
  • Table 97: Sales Forecasts ($) for HBV Vaccines in Japan, 2012-2022
  • Table 98: Japan HBV Vaccine Market - Drivers and Barriers, 2014
  • Table 99: Sales Forecasts ($) for HBV Vaccines in Canada, 2012-2022
  • Table 100: Key Events Impacting Sales for HBV Vaccines in Canada, 2014
  • Table 101: Canada HBV Vaccine Market - Drivers and Barriers, 2014
  • Table 102: Patient Population(s) Targeted for HBV Vaccination in the Pediatric Market, by Country
  • Table 103: Patient Population(s) Targeted for HBV Vaccination in the Adult Market, by Country
  • Table 104: Key Launch Dates
  • Table 105: High-Prescribing Physicians (non-KOLs) Surveyed, by Country

List of Figures

  • Figure 1: HBV Structure and the Recombinant Vaccine Development Process
  • Figure 2: Routine HBV Vaccination Coverage (%) in the United States
  • Figure 3: High-Prescriber Estimation of Pediatric HBV Vaccine Patient Share in the United States, 2014
  • Figure 4: Routine HBV Vaccination Coverage (%) in France
  • Figure 5: High-Prescriber Estimation of Pediatric HBV Vaccine Patient Share in France, 2014
  • Figure 6: Routine HBV Vaccination Coverage (%) in Germany
  • Figure 7: High-Prescriber Estimation of Pediatric HBV Vaccine Patient Share in Germany, 2014
  • Figure 8: Routine HBV Vaccination Coverage (%) in Italy
  • Figure 9: High-Prescriber Estimation of Pediatric HBV Patient Share in Italy, 2014
  • Figure 10: Routine HBV Vaccination Coverage (%) in Spain
  • Figure 11: High-Prescriber Estimation of Pediatric HBV Vaccine Patient Share in Spain, 2014
  • Figure 12: High-Prescriber Estimation of Pediatric HBV Vaccine Patient Share in the United Kingdom, 2014
  • Figure 13: High-Prescriber Estimation of Pediatric HBV Vaccine Patient Share in Japan, 2014
  • Figure 14: High-Prescriber Estimation of Pediatric HBV Vaccine Patient Share in Canada, 2014
  • Figure 15: HBV Vaccines - Clinical Trials by Country, 2014
  • Figure 16: Competitive Assessment of Late-Stage Pipeline Agents and Marketed Products in HBV Vaccines, 2012-2022
  • Figure 17: Global Sales for HBV Vaccines by Company, 2012-2022
  • Figure 18: Company Portfolio Gap Analysis in HBV Vaccines, 2012-2022
  • Figure 19: Global Sales for HBV Vaccines by Country, 2012-2022
  • Figure 20: Sales for HBV Vaccines in the United States by Vaccine, 2012-2022
  • Figure 21: Sales for HBV Vaccines in France by Vaccine, 2012-2022
  • Figure 22: Sales for HBV Vaccines in Germany by Vaccine, 2012-2022
  • Figure 23: Sales for HBV Vaccines in Italy by Vaccine, 2012-2022
  • Figure 24: Sales for HBV Vaccines in Spain by Vaccine, 2012-2022
  • Figure 25: Sales for HBV Vaccines in the United Kingdom by Vaccine, 2012-2022
  • Figure 26: Sales for HBV Vaccines in Japan by Vaccine, 2012-2022
  • Figure 27: Sales for HBV Vaccines in Canada by Vaccine, 2012-2022
Back to Top